Press & Nyheter

ViewReleaseInStandardHtml

Boule Diagnostics – Nomination Committee for the 2019 Annual General Meeting

The Annual General Meeting, (”AGM”), 2018 of Boule Diagnostics AB (publ), (”Boule”), decided that a Nomination Committee based on the ownership structure as per September 30, 2018, will be appointed to propose for the AGM of 2019 the following items:

a)     chairman of the AGM,
b)     members of the board of directors,
c)     chairman of the board,
d)     remuneration to the members of the board and remuneration for additional committee work for each board member,
e)     auditor in charge,
f)      remuneration to the auditor, and
g)     nomination process for the AGM of 2020.

Boule’s largest shareholders at the date above were AB Grenspecialisten, Svolder AB and SEB Asset Management, who combined represent over 30 percent of share capital and votes. Said shareholders have in turn nominated Emil Hjalmarsson (AB Grenspecialisten), Ulf Hedlundh (Svolder AB) and Henrietta Theorell (SEB Asset Management). The Nomination Committee has subsequently constituted and elected Ulf Hedlundh as chairman of the committee and Peter Ehrenheim, the chairman of the board, as an adjunct member of the Nomination Committee.

Shareholders who wish to contact the Nomination Committee are welcome to contact the committee’s chairman, Ulf Hedlundh, by phone +46 8-440 37 73, or by email ulf.hedlundh@svolder.se. To ensure that proposals will have enough time to be evaluated properly, proposals should be submitted by February 1, 2019 at the latest.

For further information, please contact:
Fredrik Dalborg, CEO and Group President, Boule Diagnostics AB, phone +46 705-58 51 05
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 705-46 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com 

The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CET on October 30, 2018.